Form 8-K - Current report:
SEC Accession No. 0001104659-25-018717
Filing Date
2025-02-28
Accepted
2025-02-28 08:17:59
Documents
13
Period of Report
2025-02-28
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm257885d1_8k.htm   iXBRL 8-K 21558
  Complete submission text file 0001104659-25-018717.txt   194182

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA otlk-20250228.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20250228_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20250228_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm257885d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 25682838
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)